ProCE Banner Activity

Are People With Multidrug-Resistant HIV and Limited Treatment Options Receiving the New Drugs Too Late?

Clinical Thought

Here’s why I think using newer novel agents earlier could affect virologic suppression and mortality for people with multidrug-resistant HIV.

Released: November 17, 2022

Expiration: November 16, 2023

Share

Faculty

Josep M. Llibre

Josep M. Llibre, MD, PhD

Senior Consultant
Infectious Diseases Division
Fight Infections Foundation
University Hospital Germans Trias
Badalona, Barcelona, Spain

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

ViiV Healthcare

Faculty Disclosure

Josep M. Llibre, MD, PhD: consultant/advisor/speaker: Gilead Sciences, Janssen, ViiV Healthcare.